Nanoparticles Target New Pathways to Combat Alzheimer’s Disease

Alzheimer’s disease is not limited to the accumulation of amyloid plaques and tau protein tangles. Other mechanisms, such as brain inflammation, mitochondrial dysfunction, and lysosomal disorders, play a key role in its development. These processes often appear before the classic signs of the disease and contribute to the progressive deterioration of neurons.

Nanoparticles offer a promising solution to act on these mechanisms. Thanks to their ability to cross the blood-brain barrier, they enable the delivery of therapeutic substances directly into the brain. For example, lipid-based nanoparticles, made of chitosan or gold, carry anti-inflammatory and antioxidant compounds such as curcumin or resveratrol. In animal studies, these treatments reduce brain inflammation and improve mitochondrial function, the energy powerhouses of cells. Some nanoparticles are even designed to specifically target mitochondria, thereby reducing oxidative stress and increasing cellular energy production.

Nanotechnologies also act on other pathways involved in the disease. They restore the acidity of lysosomes, cellular compartments responsible for degrading toxic waste, and improve their function. Carbon- or polymer-based nanostructures help eliminate abnormal proteins and restore cellular balance. These approaches slow the progression of the disease by reducing inflammation, optimizing energy production, and stimulating autophagy mechanisms, which allow cells to clean themselves.

Furthermore, nanoparticles modulate endoplasmic reticulum stress, a cellular structure essential for protein production. By reducing this stress, they protect neurons against cell death and limit the damage caused by the accumulation of misfolded proteins. Animal studies show that nanoparticles based on quercetin or selenium cross the blood-brain barrier and improve cognitive functions by acting on these mechanisms.

Another explored avenue is the influence of the gut-brain axis, a communication network between the digestive system and the brain. Imbalances in the gut microbiota, called dysbiosis, promote systemic and brain inflammation, thereby contributing to neurodegeneration. Nanoparticles help restore the balance of the microbiota by delivering prebiotics, probiotics, or anti-inflammatory compounds in a targeted manner. For example, chitosan-based nanoparticles protect beneficial bacteria and enhance their action in the gut, thereby reducing inflammation and its harmful effects on the brain.

Nanoparticles also act on synaptic plasticity, which is essential for memory and learning. By targeting mitochondria in synapses, they preserve their function and limit the loss of neuronal connections, a phenomenon closely linked to cognitive disorders. Magnetic or carbon-based nanoparticles also allow early imaging of synaptic changes, thus providing tools for early diagnosis.

Finally, nanotechnologies pave the way for epigenetic approaches, which aim to modify gene expression without altering their sequence. By delivering epigenetic inhibitors or modulators directly into the brain, nanoparticles could restore the balance of cellular mechanisms disrupted in the disease. Systems combining multiple functions, such as regulating oxidative stress and modulating inflammation, are under development for a more comprehensive action.

These advances show that nanoparticles could revolutionize the treatment of Alzheimer’s disease by acting on multiple fronts simultaneously. Their ability to target specific mechanisms, cross the brain’s natural barriers, and deliver treatments precisely makes them valuable tools for developing more effective therapies.

Site Sources

Official Study Source

DOI: https://doi.org/10.1186/s11671-026-04747-8

Title: Nanoparticles that target nonamyloid and nontau pathways in Alzheimer’s disease

Journal: Discover Nano

Publisher: Springer Science and Business Media LLC

Authors: Firoozeh Alavian; Arefeh Hajimohammadi